Earnings Feed
Start Free
Olema Pharmaceuticals, Inc.·4

Feb 4, 9:30 PM ET

Myles David C. 4

4 · Olema Pharmaceuticals, Inc. · Filed Feb 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Olema (OLMA) Chief Discovery Officer Myles David Receives Equity Awards

What Happened
Myles David, Olema Pharmaceuticals’ Chief Discovery & Non‑Clinical Development Officer, was granted two derivative equity awards on 2026-02-02 totaling 356,250 shares: a 250,000‑share option award and a 106,250‑share performance‑based option award. Both grants show $0 cash paid (awards issued, not purchased). These are option/award grants (transaction code A), not share sales or open‑market purchases.

Key Details

  • Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (appears timely, within the usual two‑business‑day window).
  • Awards: 250,000 shares (time‑based option) and 106,250 shares (performance‑based option) — total 356,250 derivative shares; price reported $0.00 (award/grant).
  • Vesting (per footnotes):
    • Time‑based award: 25% vests on Feb 2, 2027, then 1/48 of total vests monthly thereafter, subject to continued service.
    • Performance award: eligible to vest across two performance periods (Feb 2, 2026–Dec 31, 2029 and Feb 2, 2026–Dec 31, 2030) if Olema’s stock reaches preset 30‑day average price thresholds; portions vest upon Compensation Committee certification and subject to continued service.
  • Shares beneficially owned after transaction: not specified in the filing.

Context

  • These are derivative grants (stock options/awards). They do not represent immediate share purchases or sales and only convert into shares if vesting conditions are met and options are exercised.
  • Time‑based awards are standard retention incentives; performance awards vest only if specified stock price targets are achieved, so they are tied to the company’s future market performance.
  • Such grants are routine compensation for executives and do not by themselves indicate insider buying or selling behavior.

Insider Transaction Report

Form 4
Period: 2026-02-02
Olema Pharmaceuticals, Inc.OLMA
Myles David C.
CH. DISCOV. & NON-CLIN DEV OFF
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-02-02+250,000→ 250,000 total
    Exercise: $25.65Exp: 2036-02-01→ Common Stock (250,000 underlying)
  • Award

    Performance Stock Options (Right to Buy)

    [F2]
    2026-02-02+106,250→ 106,250 total
    Exercise: $25.65Exp: 2036-02-01→ Common Stock (106,250 underlying)
Footnotes (2)
  • [F1]25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F2]The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.
Signature
/s/ Shawnte Mitchell, Attorney-in-Fact|2026-02-04

Documents

2 files